PIK3CB and triple-negative breast carcinoma: It is unclear whether the lack of effectiveness of treatment with single-agent pan-PI3K inhibitors in triple-negative breast cancer is related to adaptive activation of compensatory signaling pathways or due to a failure to achieve sufficient target inhibition and PI3K pathway suppression due to toxicity.